Interferon-induced Mx proteins in brain tissue of multiple sclerosis patients

被引:15
作者
Al-Masri, A. N. [2 ]
Heidenreich, F. [3 ]
Walter, G. F. [1 ]
机构
[1] Klinikum Kassel, Inst Pathol, Dept Neuropathol, D-34125 Kassel, Germany
[2] Hannover Med Sch, Dept Clin Immunol, D-3000 Hannover, Germany
[3] Hannover Med Sch, Dept Neurol, D-3000 Hannover, Germany
关键词
autoimmunity; multiple sclerosis; Mx proteins; type I interferons; CELLS; IMMUNOPATHOLOGY; EXPRESSION; INFECTION; BETA-1B; GTPASE; AGENTS; BLOOD;
D O I
10.1111/j.1468-1331.2009.02573.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Recombinant interferon-beta is proven as an effective long-term treatment in patients with multiple sclerosis (MS). Unlike in other chronic inflammatory diseases, endogenous synthesis of type I interferons (IFN-alpha and IFN-beta) has not been studied extensively in MS. Mx proteins A and B (MxA and MxB) are intracellular proteins that are induced exclusively by type I IFNs. We investigated the expression of Mx proteins in post-mortem brain tissue of IFN-beta-naive MS patients as a marker for endogenous synthesis of type I IFNs. By employing monoclonal antibodies specific for MxA and MxB positive staining was detectable predominantly in reactive astrocytes within the MS plaques but also in endothelial and ependymal cells as well as in lymphocytic infiltrates. This is of interest in view of results previously published by our group and others that Mx protein concentrations measured by ELISA increase in blood samples from MS patients after IFN-beta therapy. In MS, Mx proteins are detectable in plaques suggesting endogenous synthesis of type I IFNs as part of the acute inflammatory process.
引用
收藏
页码:721 / 726
页数:6
相关论文
共 24 条
[1]   T-CELLS RESPONSIVE TO MYELIN BASIC-PROTEIN IN PATIENTS WITH MULTIPLE-SCLEROSIS [J].
ALLEGRETTA, M ;
NICKLAS, JA ;
SRIRAM, S ;
ALBERTINI, RJ .
SCIENCE, 1990, 247 (4943) :718-721
[2]   Intracellular staining of Mx proteins in cells from peripheral blood, bone marrow and skin [J].
AlMasri, AN ;
Werfel, T ;
Jakschies, D ;
vonWussow, P .
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 1997, 50 (01) :9-14
[3]   INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
DUQUETTE, P ;
GIRARD, M ;
DESPAULT, L ;
DUBOIS, R ;
KNOBLER, RL ;
LUBLIN, FD ;
KELLEY, L ;
FRANCIS, GS ;
LAPIERRE, Y ;
ANTEL, J ;
FREEDMAN, M ;
HUM, S ;
GREENSTEIN, JI ;
MISHRA, B ;
MULDOON, J ;
WHITAKER, JN ;
EVANS, BK ;
LAYTON, B ;
SIBLEY, WA ;
LAGUNA, J ;
KRIKAWA, J ;
PATY, DW ;
OGER, JJ ;
KASTRUKOFF, LF ;
MOORE, GRW ;
HASHIMOTO, SA ;
MORRISON, W ;
NELSON, J ;
GOODIN, DS ;
MASSA, SM ;
GUTTERIDGE, E ;
ARNASON, BGW ;
NORONHA, A ;
REDER, AT ;
MARTIA, R ;
EBERS, GC ;
RICE, GPA ;
LESAUX, J ;
JOHNSON, KP ;
PANITCH, HS ;
BEVER, CT ;
CONWAY, K ;
WALLENBERG, JC ;
BEDELL, L ;
VANDENNOORT, S ;
WEINSHENKER, B ;
WEISS, W ;
REINGOLD, S ;
PACHNER, A ;
TAYLOR, W .
NEUROLOGY, 1993, 43 (04) :655-661
[4]  
FOULIS AK, 1987, LANCET, V2, P1423
[5]   Immunomodulatory agents for the treatment of relapsing multiple sclerosis [J].
Galetta, SL ;
Markowitz, C ;
Lee, AG .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (19) :2161-2169
[6]  
JAKSCHIES D, 1994, HEPATOLOGY, V19, P857, DOI 10.1002/hep.1840190409
[7]   THE VIROLOGY OF DEMYELINATING DISEASES [J].
JOHNSON, RT .
ANNALS OF NEUROLOGY, 1994, 36 :S54-S60
[8]   Inhibition of nuclear import and cell-cycle progression by mutated forms of the dynamin-like GTPase MxB [J].
King, MC ;
Raposo, G ;
Lemmon, MA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (24) :8957-8962
[9]   Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS [J].
Kracke, A ;
von Wussow, P ;
Al-Masri, AN ;
Dalley, G ;
Windhagen, A ;
Heidenreich, F .
NEUROLOGY, 2000, 54 (01) :193-199
[10]   Historical developments in the research of interferon receptors [J].
Krause, Christopher D. ;
Pestka, Sidney .
CYTOKINE & GROWTH FACTOR REVIEWS, 2007, 18 (5-6) :473-482